- Home
- WALD vs ABOS Comparison
WALD vs ABOS Comparison
Compare WALD & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WALD | ABOS |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United Kingdom | United States |
| Employees | 364 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 197.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WALD | ABOS |
|---|---|---|
| Price | $1.65 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.00 | ★ $8.00 |
| AVG Volume (30 Days) | 360.6K | ★ 361.4K |
| Earning Date | 03-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.89 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $1.19 |
| 52 Week High | $3.22 | $3.60 |
Technical Indicators
Market Signals| Indicator | WALD | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 42.97 |
| Support Level | $1.47 | $2.13 |
| Resistance Level | $1.63 | $2.45 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 0.00 | 16.67 |
Price Performance
Historical ComparisonAbout WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.